Investors

Media Coverage

NASDAQ: ENVB

Overview
Press Releases
Media Coverage
Events + Presentations
Stock Information
SEC Filings
Corporate Governance
News Alerts

Media Coverage

U.S. approval for psychedelic drug MDMA nears after success in clinic [Labiotech]

September 22, 2023

Enveric Biosciences Nabs U.S. Patent For Novel Psilocybin Derivatives, Details Here [Benzinga]

September 22, 2023

Enveric Receives Patent For Psilocybin Molecules [Green Market Report]

September 20, 2023

NASDAQ-Listed Enveric To Split Into Two Companies, One For Cannabinoids, One For Psychedelics

May 11, 2022

Enveric Offers Investors Rare Exposure To Both Cannabis And Psychedelic Industries [Benzinga]

April 19, 2022

Bob Dagher, Chief Medical Officer at Enveric Biosciences [The Green Rush]

March 31, 2022

Inside the Race to Make Psychedelics ‘Mainstream Medicines’ [Endpoints News]

March 29, 2022

Five Companies Developing Second Generation Psychedelics For Mental Health [Benzinga]

March 24, 2022

Groundbreaking Trial to Explore Psychedelic Therapy for Cancer Distress [Psychedelic Health]

February 21, 2022

Psilocybin For Cancer Related Distress: Enveric To Launch Clinical Trial In Partnership With University of Calgary [via Benzinga]

February 17, 2022

‹
1
…
9
10
11
12
13
…
17
›

Company

Team

Psybrary™

Pipeline

Investors

Contact

Sign Up for Updates

© 2026 Enveric Biosciences | Terms of Use | Privacy Policy

Enveric Biosciences is a development stage company that markets no products at this time. The content of this site is not intended to be promotional or to suggest any product or use of a product that has been approved by any regulatory body.